Eric Duane Foster net worth and biography

Eric Foster Biography and Net Worth

Chief Commercial Officer of Ardelyx

Eric has served as Ardelyx’s Chief Commercial Officer since August 2024. Before Ardelyx, Eric was a member of the executive team at Horizon Therapeutics, in the role of Senior Vice President and U.S. General Manager. Horizons was acquired by Amgen in October 2023.

Over the course of his career, Eric has garnered vast experience working across complex specialty and rare disease markets by implementing change management initiatives that drive growth in sales, marketing, and payor services. He has successfully provided strategic direction helping sales and marketing professionals to capitalize on untapped markets and revenue streams.

Prior to his time at Horizon Therapeutics, from 2010 to 2021, Eric held roles of increasing responsibility within the sales and marketing organization at GlaxoSmithKline across a variety of immunology and rare disease products, including serving as Vice President of Immunology Marketing, Senior Global Marketing Director and Field Sales Vice President. Eric began his career in sales and market access at Johnson & Johnson.
He previously served as a board member of the N.C. Arthritis Foundation and has been nominated for and received several leadership awards both inside and outside of the companies he has worked with.

Eric holds a Bachelor of Arts in Economics degree from the University of Georgia and a Master of Business Administration from Auburn University.

What is Eric Duane Foster's net worth?: The estimated net worth of Eric Duane Foster is at least $1.78 million as of August 21st, 2025. Mr. Foster owns 301,498 shares of Ardelyx stock worth more than $1,784,868 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Foster may own. Learn More about Eric Duane Foster's net worth.
How do I contact Eric Duane Foster?: The corporate mailing address for Mr. Foster and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Eric Duane Foster's contact information.
Has Eric Duane Foster been buying or selling shares of Ardelyx?: Eric Duane Foster has not been actively trading shares of Ardelyx within the last three months. Most recently, Eric Duane Foster sold 15,308 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $5.93, for a transaction totalling $90,776.44. Following the completion of the sale, the insider now directly owns 301,498 shares of the company's stock, valued at $1,787,883.14. Learn More on Eric Duane Foster's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, Ardelyx insiders bought shares 7 times. They purchased a total of 1,371,406 shares worth more than $5,780,176.94. In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 580,304 shares worth more than $3,050,503.57. The most recent insider tranaction occured on November, 21st when insider Elizabeth A Grammer sold 5,995 shares worth more than $33,212.30. Insiders at Ardelyx own 4.8% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 11/21/2025.

Eric Duane Foster Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/21/2025	Sell	15,308	$5.93	$90,776.44	301,498
5/20/2025	Sell	2,507	$4.08	$10,228.56	316,806

Eric Duane Foster Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $5.92

$5.73

$5.93

50 Day Range

MA: $5.47

$4.94

$6.13

2 Week Range

Now: $5.92

$3.21

$6.78

Volume

2,512,726 shs

Average Volume

2,556,201 shs

Market Capitalization

$1.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55